anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multispecific molecules which induce effector cellmediated killing of target cells are disclosed. The molecules are multispecific because they bind to multiple (two or more), distinct targets, one of which is an Fc receptor on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to an Fc receptor, such as an Fcggr; receptor (e.g., Fcggr;RI) or an Fcagr; receptor, and at least one other portion which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen multimer complexes comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as selfantigens, to APCs to induce andor enhance internalization (endocytosis), processing andor presentation of the antigen by the APC. Therefore, these molecules can be used to induce or enhance an immune response either in vivo or in vitro against a normally nonimmunogenic protein, such as a selfantigen. In a particular embodiment, at least one portion of the multispecific molecules comprises a humanized or human antibody or antibody fragment (e.g., ScFv or Fab) which binds to an Fc receptor or a receptor on a target cell (e. g., EGFR or HER2).
Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
A system communicates pharmaceutical verification information between a server and a node using a network. The node includes a pharmaceutical identification and verification system. The verification information includes a known spectral signature of a known pharmaceutical and a corresponding known pharmaceutical name and dosage strength of the known pharmaceutical. The server stores the verification information in a server database. The node receives the verification information from the server, stores the verification information in the client database, reads a pharmaceutical name and dosage strength from a container enclosing a pharmaceutical, obtains a detected spectral signature for the pharmaceutical, and compares the detected spectral signature to the at least one known spectral signature. The pharmaceutical identification and verification system includes a static multimodal multiplex spectrometer. The verification information can also include a spectral signature of a known container.
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia disorder that necessitates long-time electrocardiogram (ECG) data for clinical diagnosis, leading to low detection efficiency. Automatic detection of AF signals within short-time ECG recordings is challenging. To address these issues, this paper proposes a novel algorithm called Ensemble Learning and Multi-Feature Discrimination (ELMD) for the identification and detection of AF signals. Firstly, a robust classifier, BSK-Model, is constructed using ensemble learning. Subsequently, the ECG R-waves are detected, and the ECG signals are segmented into consecutive RR intervals. Time domain, frequency domain, and nonlinear features are extracted from these intervals. Finally, these features are fed into the BSK-Model to discriminate AF. The proposed methodology is evaluated using the MIT-BIH AF database. The results demonstrate that when RR intervals are employed as classification units, the specificity and accuracy of AF detection in long-time ECG data exceed 99%, showcasing a significant improvement over traditional single-model classification. Additionally, the sensitivity and accuracy achieved by testing cardiac segments are both above 96%. With a minimum requirement of only four cardiac segments, AF events can be accurately identified, thereby enabling rapid discrimination of short-time single-lead ECG AF events. Consequently, this approach is suitable for real-time and accurate AF detection using low-computational-power ECG diagnostic analysis devices, such as wearable devices.
Ultrasound guided paravertebral block (TPVB) with liposomal bupivacaine is performed in this group. 40ml of liposomal bupivacaine and saline mixture was injected to the right T4-T5, T7-T8, and bilateral T10-T11 paravertebral spaces, with 10 ml for each space. Patient-controlled intravenous analgesia (PCIA) is used for postoperative pain management.
PURPOSE: A method for manufacturing a Poria cocos extract is provided to ensure high yield using chitinase and shorten production processes. CONSTITUTION: A Poria cocos extract is produced by adding a solvent and chitinase to Poria cocos. The Poria cocos is obtained from Pinus plant root. The Pinus is P. densiflora, P. koraiensis, P. thunbergii, P. bungeana, P. massoniana, P. taiwanensis, or P. yunnanensis. The extraction solvent is water, methanol, ethanol, or a mixture thereof. The Poria cocos extract contains 0.1-10 weight% of chitinase.
The present invention relates to a contrast agent suitable for ex vivo imaging, particularly of vascular structures and renal tubular structures, and a method for ex vivo imaging. The contrast agent is a polymer comprising monomers M. The monomer comprises a backbone having 2 to 6 elements, wherein at least one element is -CH(R)- or -N(R)-. R is a moiety –E-H, -L-(NH2)m or a moiety of formula 1, with E, L, R1 and R2 being defined as described in the present specification. The monomer comprises at least one -I to allow detection via X-ray and at least one –NH2 to allow crosslinking. Furthermore, the monomer comprises polar functional groups that contribute to water solubility. To avoid extravasation and glomerular filtration, the polymers are pre-crosslinked before the vasculature of a tissue, an organ or whole animal is perfused. After perfusion, the pre-crosslinked contrast agent is further crosslinked to be retained within the tissue, organ or animal permanently.
In vitro experiments have been performed to assess the potential of tolcapone to interact with isoenzymes of cytochrome P450 (CYP). No relevant interactions with substrates for CYP 2A6 (warfarin), CYP 1A2 (caffeine), CYP 3A4 (midazolam, terfenadine, cyclosporine), CYP 2C19 (S-mephenytoin) and CYP 2D6 (desipramine) were observed in vitro. The absence of an interaction with desipramine, a drug metabolized by cytochrome P450 2D6, was also confirmed in an in vivo study where tolcapone did not change the pharmacokinetics of desipramine.

Due to its affinity to cytochrome P450 2C9 in vitro, tolcapone may interfere with drugs, whose clearance is dependent on this metabolic pathway, such as tolbutamide and warfarin. However, in an in vivo interaction study, tolcapone did not change the pharmacokinetics of tolbutamide. Therefore, clinically relevant interactions involving cytochrome P450 2C9 appear unlikely. Similarly, tolcapone did not affect the pharmacokinetics of desipramine, a drug metabolized by cytochrome P450 2D6, indicating that interactions with drugs metabolized by that enzyme are unlikely. Since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these two drugs are co-administered.
In the 21st century, advances in science and technology have led to demographic changes, resulting in an increase in the elderly population. In this process, developments in the field of health such as increased preventive health services and early diagnosis and treatment of diseases played an important role. Aging is a natural process and can be defined as a decrease in an individual's physical and spiritual functions and an increase in external dependency. Adapting the elderly to this period supports psychological well-being by increasing functionality and life satisfaction. The Roy Adaptation Model aims for nurses to meet the needs of individuals to adapt, and this model can also be applied to the elderly. With technological advances, innovations such as virtual reality are used in the field of health and help improve the quality of life of the elderly. In the literature, studies examining the effects of Roy Adaptation Model and virtual reality glasses application on adaptation difficulties, life satisfaction and psychological well-being in the elderly are limited. This study aims to determine the effects of Roy Adaptation Model and virtual reality glasses application on adaptation difficulties, life satisfaction and psychological well-being in the elderly and to lay the foundation for evidence-based research. The thesis is a pre-posttest randomized controlled study with experimental and control groups. In the thesis study, data were collected as pre-post test from the elderly living in nursing homes using the Personal Information Form, Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly, and Psychological Well-Being Scale in the Elderly.In the thesis study, the experimental group was shown educational videos and nature videos with VR SHINECON 360 degree virtual reality glasses, based on the Roy adaptation model adaptation areas titles (physiological needs, self-concept area, role function area, interdependence area) twice a week for four weeks.
Ibrutinib, Fludarabine, and Pembrolizumab combination therapy will be administered in participants with High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur. Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days. Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
Dentifrices comprise a polishing agent, a water-soluble fluorine-containing compound which yields fluoride ions in aqueous solution and a buffering agent, such that when the pH of a slurry of the dentifrice is measured under the conditions hereinafter defined the pH is from 5 to 6.  (The said pH is measured at 25 DEG C for a slurry of one part by weight of the dentifrice and three parts by weight of an aqueous solution comprising 1.01 g/litre of sodium bicarbonate and 0.71 g/litre of disodium orthophosphate, said aqueous solution being adjusted to pH 7.8 with N hydrochloric acid). Polishing agents specified are silica, a hydrated alumina-silica mixture, calcium pyrophosphate and mixtures of water-insoluble sodium metaphosphate with calcium pyrophosphate, dicalcium orthophosphate, silica or alumina; synthetic organic polymers (unspecified) may also be used.  Specified fluorine compounds are sodium, potassium, lithium, ammonium, germanium, aluminium and stannous fluorides and stannous chloro-fluoride. Suitable buffering agents include the mixtures NaH2PO4/Na2HPO4, acetic acid/sodium acetate, malic acid/sodium malate and sorbic acid/sodium sorbate. A germicide may be included in the dentifrice, e.g. 2, 21-methylene-bis (3, 4, 6-trichlorophenol), 3, 41, 5-tribromosalicylanilide and 3, 4, 41-trichlorocarbanilide.
Gut dysbiosis refers to an imbalance in gut microbiota composition and function. Opuntia ficus-indica extract has been shown to modulate gut microbiota by improving SCFA production in vivo and gastrointestinal discomfort (GD) in humans. The aim of this study was to demonstrate the efficacy of OdiliaTM on gastrointestinal health by changing the microbial diversity of species involved in inflammation, immunity, oxidation, and the brain-gut-muscle axis. A randomized, double-blind clinical trial was conducted in 80 adults with gut dysbiosis. The intervention consisted of a 300 mg daily intake of OdiliaTM (n = 40) or maltodextrin as a placebo (n = 40), administered for 8 weeks. Intervention effect was evaluated using 16S metagenomics and GIQLI/GSAS scores at baseline, at 4 and 8 weeks. Eight weeks of OdiliaTM supplementation positively modulates gut microbiota composition with a significant reduction in the Firmicutes to Bacteroidetes ratio (p = 0.0012). Relative abundances of beneficial bacteria (Bacteroides and Clostridium_XIVa) were significantly increased (p < 0.001), in contrast to a significant reduction in pro-inflammatory bacteria (p < 0.001). Accordingly, GIQLI and GSAS scores revealed successful improvement in GD. OdiliaTM may represent an effective and well-tolerated treatment in subjects with gut dysbiosis.
Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
PURPOSE: To evaluate the feasibility of further reducing the incidence of occult endometrial cancer in women undergoing hysterectomy for benign gynecological indications.
METHODS: Patients who underwent hysterectomies for presumed benign gynecologic conditions at Peking Union Medical College Hospital were retrospectively identified. Patients with occult endometrial cancer, which was defined as endometrial cancer diagnosed on postoperative histopathology with no preoperative confirmed malignancy, were selected.
RESULTS: 24/7558 (0.32%; 95% CI 0.20-0.47%) patients undergoing hysterectomy for benign indications had occult endometrial cancer. Asymptomatic patients with normal endometrial imaging all tended to have favorable pathology. Heavy menstrual bleeding was the most overlooked AUB pattern in the premenopausal group. In the postmenopausal group, all the patients with serous adenocarcinoma or G3 endometrioid adenocarcinoma histology/stage T1b disease/LVSI space invasion had a history of persistent or recurrent PMB ≥ 6 months and/or an intracavitary lesion > 20 mm in diameter. 3/4 of the samples of the postmenopausal patients did not have adequate endometrium for evaluation.
CONCLUSION: To further reduce the incidence of occult endometrial cancer, physicians should focus on the patient's bleeding pattern and actively implement endometrial sampling whenever indicated. Transvaginal ultrasonography is a valuable preoperative evaluation. Hysteroscopy with directed biopsy is the preferred procedure in postmenopausal patients.
A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
Severe asherman syndrome will lead to infertility, and the most common method to treat asherman syndrome is operating to dissect adhesions. In order to prevent the postoperative re-adhesion, many physical isolation measures have been tried. However, they don't improve the microenvironment of endometrial regeneration. It's reported that bone marrow mononuclear cells have good effects on the functional recovery of injured uterus. This study will determine whether collagen scaffolds loaded with autologous bone marrow mononuclear cells will be more effective than Foley balloon catheters at treating infertile women with severe intrauterine adhesions who have taken hysteroscopic adhesiolysis. In addition, the study will be carried out in 2 centers, one is the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, the other is Changzhou Maternal and Child Health Care Hospital that is in Jiangsu Province.
Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
After patient selection through "non-probability consecutive sampling" Investigator recorded baseline characteristics of our patients including age, gender and body mass index (BMI). Once recorded, patients will be randomly divided into two equal groups (each containing 37 patients). In group A or "incentive spirometry group" patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file. In group B or "no incentive spirometry group" patients were not asked to perform incentive spirometry.

After this, all the included patients underwent upper abdominal surgery by expert surgical team under general anesthesia. Type of surgery (Laparoscopic Cholecystectomy / Open Cholecystectomy / perforated duodenal repair/ Epigastric Hernia Repair / Gastrojejunostomy) and duration for which patient was on ventilator support (in minutes) was documented. After surgery, all the patients were given adequate analgesia and antibiotics as per standard hospital protocol. Patients were assessed at 48 hours after surgery for presence of basal atelectasis which will be diagnosed clinically by presence of new onset respiratory symptoms "cough, crackles, tachypnea and reduced breath sounds at bases" and by chest X-ray "presence of basal opacification, crowded air bronchograms, crowded pulmonary vasculature and compensatory hyper-expansion of surrounding unaffected lung".

"The statistical package for social sciences (SPSS) version 22 software was used for statistical analysis of the data. Normality of test will be checked using Shapiro-Wilk test which showed that age and BMI were normally distributed while duration of ventilatory support was non-normal data. For qualitative variables frequency and percentages were used, whereas for quantitative data mean ± standard deviation and median (IQR) were used. Qualitative variables (gender, type of surgery and presence of basal atelectasis) were compared between groups with the use of chi-square test. Quantitative variable (age and BMI) were compared between groups using Student t-test while (duration of ventilatory support) were compared between groups using Mann-Whittney U-test. A p-value of ≤ 0.05 was considered significant".
Anyone considering the use of atomoxetine in a child or adolescent must balance the potential risks with the clinical need [see Boxed Warning and Warnings and Precautions (5.1)]. 
    The pharmacokinetics of atomoxetine in children and adolescents are similar to those in adults. The safety, efficacy, and pharmacokinetics of atomoxetine in pediatric patients less than 6 years of age have not been evaluated. 
    A study was conducted in young rats to evaluate the effects of atomoxetine on growth and neurobehavioral and sexual development. Rats were treated with 1, 10, or 50 mg/kg/day (approximately 0.2, 2, and 8 times, respectively, the maximum human dose on a mg/m2 basis) of atomoxetine given by gavage from the early postnatal period (Day 10 of age) through adulthood. Slight delays in onset of vaginal patency (all doses) and preputial separation (10 and 50 mg/kg), slight decreases in epididymal weight and sperm number (10 and 50 mg/kg), and a slight decrease in corpora lutea (50 mg/kg) were seen, but there were no effects on fertility or reproductive performance. A slight delay in onset of incisor eruption was seen at 50 mg/kg. A slight increase in motor activity was seen on Day 15 (males at 10 and 50 mg/kg and females at 50 mg/kg) and on Day 30 (females at 50 mg/kg) but not on Day 60 of age. There were no effects on learning and memory tests. The significance of these findings to humans is unknown.
The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized pharmaceutical composition. The pharmaceutical compositions of the present disclosure have an ethanol content in the range from about 12000 ppm to about 25000 ppm. The composition of the present disclosure, in certain embodiments, is stable following 36 months of storage, wherein the total impurities do not exceed 0.2%. The pharmaceutical compositions of the present disclosure may be used for the treatment of neonatal seizures. The present invention further relates to methods of preparing a lyophilized composition of phenobarbital sodium and to lyophilized pharmaceutical compositions of phenobarbital sodium prepared using the same.
The invention relates to a method for preparing oryzanol microemulsion. The transparent or most transparent, clear and stable microemulsion is prepared by dissolving oryzanol into plant oil, adopting a nonionic surface active agent as an emulsifying agent, adopting fatty alcohol as an auxiliary agent and adding water or a sodium chloride aqueous solution and stirring. The oryzanol content in the microemulsion can be adjusted in a certain range as required, the maximal content of the oryzanol is 3 percent by weight, and the water content is in a range of 50-91 percent. The particle diameter of a microemulsion drop is in a range of 8-100nm, and the microemulsion is not turbid and is not delaminated in a temperature range of 20-90 DEG C. The oryzanol microemulsion prepared by the invention has transparent or most transparent, clear and stable property, the oryzanol content in the microemulsion can be adjusted in the certain range as required, and the maximal content of the oryzanol is 3 percent. The water content is in the range of 50-91 percent. The particle diameter of the microemulsion drop is in the range of 8-100nm. The microemulsion is not turbid and is not delaminated in the temperature range of 20-90 DEG C.
NEW MATERIAL:The phenylpiperazine derivative of formula I (R1 is lower alkyl; R2, R3 and R4 are H, halogen, lower alkyl, lower alkoxy, OH, trifluoro- methyl, lower alkoxycarbonyl, or adjacent two groups of R2, R3 and R4 together form methylenedioxy group; n is 2-6), and its salt. EXAMPLE:1-(2-Methoxyphenyl)-4-(2-benzoylaminoethyl)piperazine. USE:It has hypotensive activity, cerebral blood flow increasing activity, and the activities to decrease the pulse rate and suppress the ventricular arrhythmia caused by myocardial ischemia, and is useful as a remedy for circulatory diseases. PROCESS:The compound of formula I can be prepared, e.g. by reacting the compound of formula II with the compound of formula III in an inert solvent such as benzene, toluene, etc. in the presence of a catalyst comprising a base such as sodium carbonate, triethylamine, etc. under heating and stirring.
Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.